HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer

Eguchi,Ryoji; Eguchi,Ryoji; Eguchi,Ryoji; Eguchi,Ryoji; Eguchi,Ryoji; Eguchi,Ryoji; Wakabayashi,Ichiro; Wakabayashi,Ichiro; Wakabayashi,Ichiro; Wakabayashi,Ichiro; Wakabayashi,Ichiro; Wakabayashi,Ichiro

doi:10.3892/or.2020.7580

HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer

Authors:
- Ryoji Eguchi
- Ichiro Wakabayashi
View Affiliations

Affiliations: Department of Environmental and Preventive Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan
Published online on: April 9, 2020 https://doi.org/10.3892/or.2020.7580
Pages: 14-28
Copyright: © Eguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) accounts for over 80% of all diagnosed lung cancer cases. Lung cancer is the leading cause of cancer‑related deaths worldwide. Most NSCLC cells overexpress vascular endothelial growth factor‑A (VEGF‑A) which plays a pivotal role in tumour angiogenesis. Anti‑angiogenic therapies including VEGF‑A neutralisation have significantly improved the response rates, progression‑free survival and overall survival of patients with NSCLC. However, the median survival of these patients is shorter than 18 months, suggesting that NSCLC cells secrete VEGF‑independent angiogenic factors, which remain unknown. We aimed to explore these factors in human NSCLC cell lines, A549, Lu99 and EBC‑1 using serum‑free culture, to which only EBC‑1 cells could adapt. By mass spectrometry, we identified 1,007 proteins in the culture supernatant derived from EBC‑1 cells. Among the identified proteins, interleukin‑8 (IL‑8), macrophage migration inhibitory factor (MIF), galectin‑1, midkine (MK), IL‑18, galectin‑3, VEGF‑A, hepatoma‑derived growth factor (HDGF), osteopontin (OPN), connective tissue growth factor (CTGF) and granulin (GRN) are known to be involved in angiogenesis. Tube formation, neutralisation and RNA interference assays revealed that VEGF‑A and HDGF function as angiogenic factors in EBC‑1 cells. To confirm whether VEGF‑A and HDGF also regulate angiogenesis in the other NSCLC cell lines, we established a novel culture method. NSCLC cells were embedded in collagen gel and cultured three‑dimensionally. Tube formation, neutralisation and RNA interference assays using the three‑dimensional (3D) culture supernatant showed that VEGF‑A and HDGF were not angiogenic factors in Lu99 cells. By gene microarray in EBC‑1 and Lu99 cells, we identified 61 mRNAs expressed only in Lu99 cells. Among these mRNAs, brain‑derived neurotrophic factor (BDNF), fibroblast growth factor‑2 (FGF‑2) and FGF‑5 are known to be involved in angiogenesis. Tube formation and neutralisation assays clarified that FGF‑2 functions as an angiogenic factor in Lu99 cells. These results indicate that HDGF enhances VEGF‑dependent angiogenesis and that FGF‑2 is a VEGF‑independent angiogenic factor in human NSCLC cells.

View Figures

View References

1	Inoue M, Sawada N, Matsuda T, Iwasaki M, Sasazuki S, Shimazu T, Shibuya K and Tsugane S: Attributable causes of cancer in Japan in 2005-systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan. Ann Oncol. 23:1362–1369. 2012. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Villaruz LC and Socinski MA: The role of anti-angiogenesis in non-small-cell lung cancer: An update. Curr Oncol Rep. 17:262015. View Article : Google Scholar : PubMed/NCBI
4	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
5	Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar : PubMed/NCBI
6	Ebos JM and Kerbel RS: Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, et al: A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 99:186–193. 2016. View Article : Google Scholar : PubMed/NCBI
8	Eguchi R, Nakano T and Wakabayashi I: Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells. Oncogene. 36:714–722. 2017. View Article : Google Scholar : PubMed/NCBI
9	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
10	Ung TH, Madsen HJ, Hellwinkel JE, Lencioni AM and Graner MW: Exosome proteomics reveals transcriptional regulator proteins with potential to mediate downstream pathways. Cancer Sci. 105:1384–1392. 2014. View Article : Google Scholar : PubMed/NCBI
11	Bosque A, Dietz L, Gallego-Lleyda A, Sanclemente M, Iturralde M, Naval J, Alava MA, Martínez-Lostao L, Thierse HJ and Anel A: Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. Oncotarget. 7:29287–29305. 2016. View Article : Google Scholar : PubMed/NCBI
12	Keeley EC, Mehrad B and Strieter RM: CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 106:91–111. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chesney JA and Mitchell RA: 25 Years On: A retrospective on migration inhibitory factor in tumor angiogenesis. Mol Med. 21 (Suppl 1):S19–S24. 2015. View Article : Google Scholar : PubMed/NCBI
14	Thijssen VL and Griffioen AW: Galectin-1 and −9 in angiogenesis: A sweet couple. Glycobiology. 24:915–920. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kadomatsu K, Bencsik P, Gorbe A, Csonka C, Sakamoto K, Kishida S and Ferdinandy P: Therapeutic potential of midkine in cardiovascular disease. Br J Pharmacol. 171:936–944. 2014. View Article : Google Scholar : PubMed/NCBI
16	Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G and Arra C: Interleukin 18: Friend or foe in cancer. Biochim Biophys Acta. 1836:296–303. 2013.PubMed/NCBI
17	Funasaka T, Raz A and Nangia-Makker P: Galectin-3 in angiogenesis and metastasis. Glycobiology. 24:886–891. 2014. View Article : Google Scholar : PubMed/NCBI
18	Bao C, Wang J, Ma W, Wang X and Cheng Y: HDGF: A novel jack-of-all-trades in cancer. Future Oncol. 10:2675–2685. 2014. View Article : Google Scholar : PubMed/NCBI
19	Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, et al: Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 28:3412–3422. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ramazani Y, Knops N, Elmonem MA, Nguyen TQ, Arcolino FO, van den Heuvel L, Levtchenko E, Kuypers D and Goldschmeding R: Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol 68–69. 44–66. 2018. View Article : Google Scholar
21	He Z and Bateman A: Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl). 81:600–612. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kermani P and Hempstead B: Brain-derived neurotrophic factor: A newly described mediator of angiogenesis. Trends Cardiovasc Med. 17:140–143. 2007. View Article : Google Scholar : PubMed/NCBI
23	Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, Awada AH and Shamseddine A: Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 84:149–160. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vorosmarty B, Brankovic J, Lackner A, Leopoldi A, et al: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Oncotarget. 8:87750–87762. 2017. View Article : Google Scholar : PubMed/NCBI
25	Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, Yamamoto H, Sato J and Kishimoto S: Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 183:273–284. 1989. View Article : Google Scholar : PubMed/NCBI
26	Everett AD, Narron JV, Stoops T, Nakamura H and Tucker A: Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol. 286:L1194–L1201. 2004. View Article : Google Scholar : PubMed/NCBI
27	Ren H, Chu Z and Mao L: Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 8:1106–1112. 2009. View Article : Google Scholar : PubMed/NCBI
28	Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR and Mao L: Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 22:3230–3237. 2004. View Article : Google Scholar : PubMed/NCBI
29	Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K and Kawahara K: Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep. 13:1075–1080. 2005.PubMed/NCBI
30	Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA, Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun. 435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
31	Ke Y, Zhao W, Xiong J and Cao R: Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 587:3153–3157. 2013. View Article : Google Scholar : PubMed/NCBI
32	Guo H, Li W, Zheng T and Liu Z: MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol. 35:8861–8866. 2014. View Article : Google Scholar : PubMed/NCBI
33	Thirant C, Galan-Moya EM, Dubois LG, Pinte S, Chafey P, Broussard C, Varlet P, Devaux B, Soncin F, Gavard J, et al: Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells. 30:845–853. 2012. View Article : Google Scholar : PubMed/NCBI
34	Enomoto H, Nakamura H, Liu W, Iwata Y, Nishikawa H, Takata R, Yoh K, Hasegawa K, Ishii A, Takashima T, et al: Down-regulation of HDGF inhibits the growth of hepatocellular carcinoma cells in vitro and in vivo. Anticancer Res. 35:6475–6479. 2015.PubMed/NCBI
35	Bacic I, Karlo R, Zadro AS, Zadro Z, Skitarelic N and Antabak A: Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA). Oncol Lett. 15:2335–2339. 2018.PubMed/NCBI
36	Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, Gliksman M, Goy A and Suh KS: Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 7:44735–44762. 2016. View Article : Google Scholar : PubMed/NCBI
37	Hu M, Hu Y, He J and Li B: Prognostic value of basic fibroblast growth factor (bFGF) in lung cancer: A systematic review with meta-analysis. PLoS One. 11:e01473742016. View Article : Google Scholar : PubMed/NCBI
38	Hu MM, Hu Y, Gao GK, Han Y, Shi GL and Li BL: Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients. Thorac Cancer. 6:450–457. 2015. View Article : Google Scholar : PubMed/NCBI
39	Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Busund LT and Bremnes RM: Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol. 4:463–471. 2009. View Article : Google Scholar : PubMed/NCBI
40	Wang S, Qin Y, Wang Z, Xiang J, Zhang Y, Xu M, Li B, Xia Y, Zhang P and Wang H: Construction of a human monoclonal antibody against bFGF for suppression of NSCLC. J Cancer. 9:2003–2011. 2018. View Article : Google Scholar : PubMed/NCBI
41	La Venuta G, Zeitler M, Steringer JP, Muller HM and Nickel W: The startling properties of fibroblast growth factor 2: How to exit mammalian cells without a signal peptide at hand. J Biol Chem. 290:27015–27020. 2015. View Article : Google Scholar : PubMed/NCBI
42	Sorensen V, Nilsen T and Wiedlocha A: Functional diversity of FGF-2 isoforms by intracellular sorting. Bioessays. 28:504–514. 2006. View Article : Google Scholar : PubMed/NCBI
43	Muller HM, Steringer JP, Wegehingel S, Bleicken S, Munster M, Dimou E, Unger S, Weidmann G, Andreas H, Garcia-Saez AJ, et al: Formation of disulfide bridges drives oligomerization, membrane pore formation, and translocation of fibroblast growth factor 2 to cell surfaces. J Biol Chem. 290:8925–8937. 2015. View Article : Google Scholar : PubMed/NCBI
44	Dimou E, Cosentino K, Platonova E, Ros U, Sadeghi M, Kashyap P, Katsinelos T, Wegehingel S, Noe F, Garcia-Saez AJ, et al: Single event visualization of unconventional secretion of FGF2. J Cell Biol. 218:683–699. 2019. View Article : Google Scholar : PubMed/NCBI
45	Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, Ogawa O, Komeda M and Tabata Y: Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release. 99:281–292. 2004. View Article : Google Scholar : PubMed/NCBI